Black Diamond Therapeutics Inc (BDTX NASDAQ) stock market data APIs
$3.265
0.13(4%)
as of September 12, 2025
Try our APIs with
free plan!
Black Diamond Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
3.265
Open
3.3936
High
3.4548
Low
3.2132
52 wk Range
1.195-5.69
Market Cap
185 M
P/E Ratio
13.5417
Shares Outstanding
56 935 K
Revenue
70 000 K
EPS
-0.19
Beta
2.941
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Black Diamond Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Black Diamond Therapeutics Inc data using free add-ons & libraries
Get Black Diamond Therapeutics Inc Fundamental Data
Black Diamond Therapeutics Inc Fundamental data includes:
- Net Revenue: 70 000 K
- EBITDA: 7 994 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.2467
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Black Diamond Therapeutics Inc News
New
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Black Diamond Therapeutics, Inc. (BDTX) is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s lead pipeline candidate is silevertinib. ...
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Black Diamond Therapeutics, Inc. (BDTX) has put up a stellar performance so far this year. Shares of this clinical-stage oncology company surged 51.1% in the past six months against the industry’s d...
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
Black Diamond Therapeutics, Inc.’s BDTX lead pipeline candidate, silevertinib, is a brain penetrant, fourth-generation epidermal growth factor receptor (“EGFR”) MasterKey inhibitor targeting epi...
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership oppo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
